KKR completed its $5.89 billion acquisition of Integer Holdings on August 29, marking the largest healthcare private equity transaction of the month in a period when global dealmaking volumes fell sharply across other sectors. The medical device manufacturer, which produces cardiac rhythm management systems and surgical implants, moved from public markets into KKR's portfolio at a 31% premium to its 90-day volume-weighted average price.

Global private equity deal volumes declined 18% month-over-month in August, with technology and consumer sectors seeing the steepest pullbacks. Healthcare accounted for $12.4 billion of the month's $38.7 billion in total PE dealmaking, according to Dealogic data through August 30. KKR's Integer transaction alone represented nearly half that healthcare total, underscoring the binary nature of current private equity deployment: selective concentration in regulated, cash-generative verticals versus broad capital preservation elsewhere.

Integer operates in the medical device supply chain with 83% of revenue derived from original equipment manufacturing for cardiovascular and neuromodulation devices. The company reported $1.46 billion in trailing twelve-month revenue as of Q2 2024, with EBITDA margins near 22%. KKR's thesis centers on consolidating fragmented OEM capacity while Integer's existing relationships with Medtronic, Abbott, and Boston Scientific provide immediate cross-sell pathways for bolt-on acquisitions. The firm signaled intent to deploy an additional $800 million to $1.2 billion in tuck-in M&A over the next 18 months, targeting smaller precision component manufacturers in the $50 million to $200 million revenue range.

This deal continues KKR's pattern of building vertically integrated healthcare platforms during periods of public market dislocation. The firm deployed $7.2 billion in healthcare transactions over the prior twelve months, including its $2.1 billion take-private of Envision Healthcare's ambulatory surgery centers in October 2023. Healthcare private equity multiples remain elevated relative to broader PE averages—Integer transacted at roughly 11.2x trailing EBITDA versus the market median of 9.4x—but the sector's regulatory moats and demographic tailwinds justify the premium for allocators seeking five-to-seven-year hold periods.

Allocators should monitor KKR's post-close capital deployment velocity into Integer's tuck-in pipeline, with the first bolt-on acquisition likely announced within 90 to 120 days. The firm's ability to compress OEM production timelines while expanding margins will determine whether this becomes a platform return or a levered dividend recap. Competitor activity from Apollo, Blackstone, and TPG in medical device OEM targets with revenue between $300 million and $800 million will signal whether this consolidation wave has another 12 to 18 months of runway or if multiples have already compressed the arbitrage.

Integer's Q3 earnings, scheduled for late October, will be the first private report. Watch for any retained management equity re-ups or departures within the 60-day post-close window.